Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B82—NANOTECHNOLOGY
  • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
  • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

• compositions for oral administration comprising an active substance and a cyclodextrin.
• the present invention relates to pharmaceutical compositions which can be administered orally, comprising an active substance belonging to the family of substituted benzhydrylpiperazines and a cyclodextrin.
• patent GB 817231 in the name of the applicant describes substituted benzhydrylpiperazines corresponding to the general formula
• R and R 1 independently of one another represent a hydrogen or halogen atom, an alkyl or alkoxy group, R and R possibly being in the ortho, meta or para position, and n represents the number 1 or 2, as well as their pharmaceutically acceptable salts.
• Patent EP 58146 in the name of the applicant describes substituted benzhydrylpiperazines corresponding to the general formula in which L represents a group -OH or -NH2, X and X ', taken in isolation, represent a hydrogen atom, a halogen atom, a linear or branched C1 or C4 alkoxy radical, or a trifluoromethyl radical, m is 1 or 2, n is 1 or 2, and their pharmaceutically acceptable salts.
• compositions which can be administered orally containing this type of compound are of the conventional type.
• administration is by swallowing through the simultaneous absorption of liquid.
• absorption must be done without simultaneous absorption of liquid (pre or postoperative conditions, absence of drinking water, etc.)
• a conventional mode of administration is not suitable because of the extremely bitter taste of these substituted benzhydrylpiperazines.
• US Pat. No. 3,558,600 describes a method for masking the bitter taste of antihistamines belonging to the family of substituted l- (p-chlorobenzhydryl) -piperazines, which consists in transforming the active substance in the form of free base into its salt a long chain alkyl sulfate, such as stearyl sulfate, for example.
• Another known method for masking the taste of active ingredients consists in forming an inclusion complex between the active ingredient and a cyclodextrin.
• the masking of the taste comes from the imprisonment of the active ingredient which cannot be released during passage through the mouth.
• this solution to the problem of taste masking gives rise to another problem particular to the masking of the taste of pharmaceutically active substances administered orally, namely, the problem of the bioavailability and the speed of action of the active principle. Indeed, if the association constant of the inclusion complex is too large, the active ingredient may not be release easily enough to allow good absorption into the gastrointestinal tract. In this case, the expected therapeutic effect cannot be obtained.
• Patent EP 399902 mentions this double problem specific to pharmaceutical compositions which can be administered orally, namely the masking of taste associated with good bioavailability.
• This patent describes lyophilized and porous pharmaceutical forms comprising, in addition to the conventional excipients and additives for this type of formulation, the active principle and a cyclodextrin, as well as processes for preparing these pharmaceutical forms.
• Pharmaceutical compositions containing the following active principles are described in the exemplary embodiments of the invention: ketoprofen, trimipramine methanesulfonate, zopiclone, phenobarbital, vitamin A, lemon essence, pritinamycin or vitamin D3.
• the applicant has therefore set itself the objective of seeking new pharmaceutical compositions allowing oral administration of pharmaceutical substances belonging to the family of substituted benzhydrylpiperazines easier than the current compositions allow, while ensuring good bioavailability of the substance active.
• cyclodextrins which can be used according to the present invention can be chosen from ⁇ , ⁇ or ⁇ cyclodextrins, or from the alkylated or hydroxyalkylated derivatives of the latter, such as l r heptakis (2,6-di-o-methyl) - ⁇ -cyclodextrin (commonly abbreviated DIMEB), randomly methylated ⁇ -cyclodextrin (commonly abbreviated RAMEB) and erydroxypropyl ⁇ -cyclodextrin (commonly abbreviated HP ⁇ CD).
• DIMEB l r heptakis (2,6-di-o-methyl) - ⁇ -cyclodextrin
• RAMEB randomly methylated ⁇ -cyclodextrin
• HP ⁇ CD erydroxypropyl ⁇ -cyclodextrin
• compositions according to the present invention can be in various forms which can be administered orally.
• the pharmaceutical compositions according to the present invention can be in the form of dry syrups, chewable tablets, granules or sublingual tablets which are particularly suitable for administration by the oral route without simultaneous absorption of liquid.
• the excipients used are the conventional excipients used for this type of composition.
• diluents such as polyols (mannitol, sorbitol, sucrose, etc.) and flavorings.
• any conventional excipient can be used which provides good compression parameters such as diluents (mannitol, sorbitol, etc.), disintegrating or bulking agents (polyvinylpolypyrrolidone, croscarmellose sodium, starches and derivatives, cellulose and derivatives. %), lubricating agents (magnesium stearate %), flow agents (aerosil 200 %) and flavorings.
• the excipients mentioned above can be used, choosing from those which are water-soluble.
• the complex of the active substance with cyclodextrin can be prepared beforehand, for example, by kneading the active substance and cyclodextrin in the presence of water or by preparing an aqueous solution containing the active substance and cyclodextrin in the desired molar ratio.
• the active substance and cyclodextrin can be simply mixed with the other excipients and adjuvants.
• the solubility of hydrophobic molecules in water is increased in the presence of cyclodextrins, both with regard to the rate of solubilization and the amount of active substance solubilized.
• the modification of the water solubility of a hydrophobic active substance in the presence of cyclodextrin therefore constitutes a method commonly used to demonstrate the formation of an inclusion complex (see J. SZETLI, in V.F.
• cetirizine dihydrochloride is well soluble in water at neutral pH, its solubility is much lower when the pH is between 2.5 and 3.5 (solubility of the order of 1 g / 100 ml).
• the modification of the solubility of cetirizine dihydrochloride in water at pH 3.4 was examined in the presence of ⁇ -cyclodextrin, in order to demonstrate the formation of an inclusion complex between cetirizine and ⁇ -cyclodextrin.
• Solution A contained cetirizine dihydrochloride in water at pH 3.4;
• solution B contained cetirizine dihydrochloride and ⁇ -cyclodextrin in a 1: 1 molar ratio in water at pH 3.4.
• These two solutions were stirred at room temperature until the thermodynamic equilibrium was reached. After stirring, only a very small amount of cetirizine (1 g / 100 ml of water) can be dissolved in solution A.
• Solution B on the other hand, made it possible to dissolve 27 g / 100 ml of cetirizine in the aqueous phase.
• ⁇ -cyclodextrin is sparingly soluble in water (1.85 g / 100 ml). Its solubility increases with the addition of cetirizine dihydrochloride, up to a molar ratio of ⁇ -cyclodextrin / cetirizine of 1: 1. At pH 3.4, the solubility of ⁇ -cyclodextrin increases by a factor of at least 30.
• Example 3 Demonstration of the formation of a complex by UV spectroscopy.
• Complexation of a host by a cyclodextrin generally results in a slight displacement of the absorption maximum in UV spectroscopy and / or in a modification of the molar extinction coefficient (J. SZETLI in Cyclodextrin Technology, Chapter 2.2.4.2, Kluwer Academy Publisher s, 1988).
• cetirizine dihydrochloride / ⁇ -cyclodextrin Different solutions containing different molar ratios of cetirizine dihydrochloride / ⁇ -cyclodextrin were prepared, and the differences in absorbance at 230 nm were determined. Indeed, cetirizine in water has a maximum absorption at 230 nm in the absence of cyclodextrin.
• Example 4 Competition for complexation with colored indicators.
• cetirizine competes with the colored indicator for the formation of an inclusion complex. Changes in the visible spectrum therefore make it possible to determine whether cetirizine forms an inclusion complex with cyclodextrin.
• Example 5 Identification of the formation of a complex by proton NMR. Nuclear magnetic resonance spectroscopy (NMR) is commonly used to demonstrate the formation of inclusion complexes with cyclodextrins (F. DJEDAINI and B. PERLY in D. DUCHENE, New Trends in Cyclodextrin and Derivatives, Chap. 6, ⁇ 2 & 3, Edition de Santé, Paris 1991, F. DJEDAINI et al., J. Pharm. Sciences, 79 (7), 643-646 (1990)).
• NMR Nuclear magnetic resonance spectroscopy
• the stoichiometry coefficient of the complex was determined by the technique of continuous variation also called "Job method" (see F. DJEDAINI et al., J. Pharm. Sciences, 79 (7), 643-646 ( 1990), P. JOB, Ann. Chim., 9, 113-134 (1928)).
• the variation of the chemical shift for proton 3 of ⁇ -cyclodextrin was taken as variable. By this method, it is determined that the complex formed has a 1: 1 stoichiometry.
• Example 6 Chewable Cetirizine Tablets Based on Polyols Cetirizine dihydrochloride (10 parts) and ⁇ -cyclodextrin (55 parts) are kneaded in the presence of water in a planetary mixer for 20 minutes. In this way, the complex is formed between cetirizine dihydrochloride and ⁇ -cyclodextrin. This mixture is then dried in an oven.
• the complex After drying, the complex is mixed with the following excipients: Sorbitol (29.45 parts, Acesulfam K (0.7 parts) Aerosil 200 (0.3 parts), Croscarmellose Na (2, 1 parts), Glycamil (1.2 part), liquorice flavor (0.25 part)
• Sorbitol 29.45 parts
• Acesulfam K 0.7 parts
• Aerosil 200 0.3 parts
• Croscarmellose Na (2, 1 parts
• Glycamil 1.2 part
• liquorice flavor (0.25 part
• the cetirizine dihydrochloride and ⁇ -cyclodextrin complex is prepared in the same manner as in Example 6.
• the excipients used are the following: Polyvinylpolypyrrolidone (35 parts), Avicel pH 101 (50 parts), Avicel CE 15 (7 parts ),
• Aerosil 200 (1 part), Magnesium stearate (1.6 part), Acesulfam K (1.4 part), Aromas
• Example 8 Dry cetirizine syrup. Two compositions A and B were prepared by mixing the ingredients listed in the Table:
• the mixture is granulated with water in a planetary mixer, then extruded.
• the extrudate obtained is dried in a fluidized air bed.
• composition C was prepared by mixing the ingredients listed in the Table:
• Impalpable sucrose qs ad 1000 The mixture is granulated with water in a planetary mixer, then extruded. The extrudate is in a fluidized air bed.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nanotechnology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Immunology (AREA)
• Biotechnology (AREA)
• Zoology (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Pulmonology (AREA)
• Biophysics (AREA)
• Crystallography & Structural Chemistry (AREA)
• General Engineering & Computer Science (AREA)
• Medical Informatics (AREA)
• Molecular Biology (AREA)
• Psychiatry (AREA)
• Anesthesiology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Publications (1)

Family

ID=3890611

Family Applications (1)

Country Status (20)

Cited By (4)

Families Citing this family (30)

Citations (3)

Family Cites Families (9)

• 1997
  • 1997-07-03 BE BE9700572A patent/BE1011251A3/fr not_active IP Right Cessation
• 1998
  • 1998-07-02 PT PT98931849T patent/PT994710E/pt unknown
  • 1998-07-02 EP EP98931849A patent/EP0994710B2/fr not_active Expired - Lifetime
  • 1998-07-02 US US09/446,735 patent/US6455533B1/en not_active Expired - Lifetime
  • 1998-07-02 ES ES98931849T patent/ES2184293T5/es not_active Expired - Lifetime
  • 1998-07-02 AU AU82015/98A patent/AU727140B2/en not_active Expired
  • 1998-07-02 CA CA002294783A patent/CA2294783C/fr not_active Expired - Fee Related
  • 1998-07-02 PL PL337794A patent/PL192348B1/pl not_active IP Right Cessation
  • 1998-07-02 IL IL13339798A patent/IL133397A/xx not_active IP Right Cessation
  • 1998-07-02 BR BR9810495-0A patent/BR9810495A/pt not_active Application Discontinuation
  • 1998-07-02 ID IDW991729A patent/ID23806A/id unknown
  • 1998-07-02 RU RU99128065/14A patent/RU2192863C2/ru not_active IP Right Cessation
  • 1998-07-02 DK DK98931849T patent/DK0994710T4/da active
  • 1998-07-02 NZ NZ501820A patent/NZ501820A/xx unknown
  • 1998-07-02 WO PCT/BE1998/000100 patent/WO1999001133A1/fr not_active Ceased
  • 1998-07-02 DE DE69808297T patent/DE69808297T3/de not_active Expired - Lifetime
  • 1998-07-02 CN CNB988067641A patent/CN1150900C/zh not_active Expired - Lifetime
  • 1998-07-02 KR KR1019997012573A patent/KR100551510B1/ko not_active Expired - Fee Related
  • 1998-07-02 JP JP50598499A patent/JP2002508773A/ja not_active Withdrawn
  • 1998-07-02 AT AT98931849T patent/ATE224717T1/de active
• 2007
  • 2007-01-12 JP JP2007004722A patent/JP2007091760A/ja active Pending

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events